No Data
No Data
Spyre Therapeutics Announces First Participant Dosed in Phase 1 Trial of SPY003, Its Novel Half-life Extended IL-23 Antibody
Wolfe Research Initiates Spyre Therapeutics at Outperform With $27 Price Target
Wolfe Research Initiates Spyre Therapeutics(SYRE.US) With Buy Rating, Announces Target Price $27
Strategic Potential of Spyre Therapeutics in Combination Therapies for Inflammatory Diseases
JonesTrading Maintains Spyre Therapeutics(SYRE.US) With Hold Rating
Spyre Therapeutics Faces Compliance Hurdles After Transition From Smaller Reporting Company Status